At $3.5m a dose, haemophilia drug is the most costly
US regulators approved CSL Behring’s haemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs $3.5m a dose, making it the world’s most expensive medicine.
CSL Behring’s Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a study of the therapy found. It also freed 94% of patients from timeconsuming and costly infusions of Factor IX, which is now used to control the potentially deadly condition.
“While the price is a little higher than expected, I do think it has a chance of being successful because existing drugs are also very expensive and haemophilia patients constantly live in fear of bleeds,” said Brad Loncar, a biotechnology investor and CEO of Loncar Investments.
“A gene therapy product will be appealing to some.”
Gene therapies can dramatically improve a range of devastating conditions by fixing their underlying causes. Novartis’s Zolgensma for babies with spinal muscular atrophy was priced at $2.1m when it was approved in 2019, while Bluebird Bio’s Zynteglo for the blood disorder beta thalassaemia came in at $2.8m earlier this year.
Pricing has been an issue for novel medicines, with high costs for drugs like Biogen’s Alzheimer’s drug Aduhelm in the US and Bluebird’s Zynteglo in Europe contributing to them becoming commercial busts. An assessment by the Institute for Clinical and Economic Review, a nonprofit that evaluates medical costs, found that a fair price for Hemgenix would be $2.93m-$2.96m.
While there have been advances in the treatment of haemophilia, measures needed to prevent and treat bleeding can erode patients’ quality of life, said Peter Marks, director of the US Food and Drug Administration’s Centre for Biologics Evaluation and Research. Hemgenix represents important progress in developing innovative therapies for people affected by the disease, he said.
Traditional haemophilia treatment infuses missing proteins, called clotting factors, that the body needs to form clots and stop bleeding. Hemgenix works by delivering a gene that can produce the missing clotting factors into the liver, where it starts working to make the Factor IX protein.
The gene therapy will be manufactured in Lexington, Massachusetts, by uniQure NV, which sold the commercialisation rights for Hemgenix to CSL Behring in 2020. About 16,000 people in the US and Europe have haemophilia B, according to uniQure. Haemophilia A is more common, affecting about five times as many people.
IT DELIVERS A GENE THAT CAN PRODUCE THE MISSING CLOTTING FACTORS